Open Access

Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs

  • Authors:
    • Cheng He
    • Yifu He
    • Huiqin Luo
    • Ming Zhang
    • Jing Wu
    • Xiaofang He
    • Yuying Fu
    • Wenju Chen
    • Jinkun Zou
  • View Affiliations

  • Published online on: May 13, 2019     https://doi.org/10.3892/ol.2019.10348
  • Pages: 792-803
  • Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study assessed whether estrogen receptor (ER)β1 is associated with the survival of patients with advanced lung adenocarcinoma, with or without mutations of the epidermal growth factor receptor (EGFR) following treatment with EGFR‑tyrosine kinase inhibitors (TKIs). Pathologically confirmed stage IV lung adenocarcinomas were assessed for EGFR mutations and ERβ1 expression. Progression‑free survival (PFS) and overall survival (OS) were estimated using the Kaplan‑Meier method and the log‑rank test. A total of 122 out of the 201 (60.7%) patients had EGFR mutations, 64 (31.8%) of which were EGFR Del19 and 58 mutations (28.9%) were EGFR exon 21 L858R mutation. The presence of EGFR mutations was significantly increased in female patients compared with male patients (P<0.001) and in non‑smokers compared with smokers (P<0.001). Patients with EGFR mutations had a significantly improved PFS and OS compared with patients without EGFR mutations treated with EGFR‑TKIs. Furthermore, ERβ1 expression was significantly increased in patients with EGFR mutations compared with patients without EGFR mutations (P=0.001). However, the median PFS (P=0.005) and OS (P=0.002) of patients carrying the EGFR exon 21 L858R mutation was significantly decreased in patients with tumors where ERβ1 cytoplasmic expression was high. The multivariate analysis demonstrated that ERβ1 expression was the only independent predictor of PFS (P=0.002) and OS (P=0.003) in patients carrying the EGFR exon 21 L858R mutation. The data demonstrated that ERβ1 expression may predict outcomes of patients with lung adenocarcinoma treated with EGFR‑TKI.
View Figures
View References

Related Articles

Journal Cover

July-2019
Volume 18 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
He C, He Y, Luo H, Zhang M, Wu J, He X, Fu Y, Chen W and Zou J: Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs. Oncol Lett 18: 792-803, 2019
APA
He, C., He, Y., Luo, H., Zhang, M., Wu, J., He, X. ... Zou, J. (2019). Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs. Oncology Letters, 18, 792-803. https://doi.org/10.3892/ol.2019.10348
MLA
He, C., He, Y., Luo, H., Zhang, M., Wu, J., He, X., Fu, Y., Chen, W., Zou, J."Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs". Oncology Letters 18.1 (2019): 792-803.
Chicago
He, C., He, Y., Luo, H., Zhang, M., Wu, J., He, X., Fu, Y., Chen, W., Zou, J."Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs". Oncology Letters 18, no. 1 (2019): 792-803. https://doi.org/10.3892/ol.2019.10348